News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Vistra positioned as a direct beneficiary of surging AI data-center power demand.
  • Shares have retraced from a 52-week high, creating a buy-the-dip entry near $141.50.
  • Analyst trade setup targets $170 with a $128 stop for a mid-term play.
  • Upside depends on securing long-term hyperscaler contracts and infrastructure joint ventures.
  • Execution and regulatory risks could invalidate the investment thesis.
  • AI-driven power scarcity may boost valuations across wholesale generators.

Latest Articles

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing

Palvella Therapeutics announced that its Chief Scientific Officer, Dr. Jeffrey Martini, has been invited to provide public comments at an upcoming FDA public workshop focused on drug repurposing. The meeting will address selection criteria and regulatory considerations for advancing repurposed therapies, particularly targeting rare and chronic dise…

HII Rally Accelerates After Q2 Beat and Massive Navy Contract Award

HII Rally Accelerates After Q2 Beat and Massive Navy Contract Award

Huntington Ingalls Industries jumped sharply in pre-market trading after reporting second-quarter 2026 results that topped consensus and announcing its Newport News Shipbuilding unit was part of a team awarded roughly $76.6 billion in U.S. Navy contract modifications. The company also declared a quarterly cash dividend, while strong results from de…

Bank of England Maps Out Three Economic Paths After Holding Rates at 3.75%

Bank of England Maps Out Three Economic Paths After Holding Rates at 3.75%

The Bank of England left its policy rate unchanged at 3.75% following a 6-3 split on the Monetary Policy Committee. In accompanying analysis it published three scenarios - central, milder and adverse - that outline alternative paths for inflation, output, and energy prices through 2029. Markets are pricing a high probability of two rate hikes by Q3…

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics announced an FDA End-of-Phase 2 meeting outcome confirming a clear regulatory pathway for its drug ATH434 targeting Multiple System Atrophy (MSA). The FDA accepted a single pivotal Phase 3 trial plus confirmatory evidence to support approval, with Phase 3 trial initiation planned by the end of 2026. The company also reported c…

Sirius XM Shares Drop After Q2 Results Spark Sell-the-News Reaction

Sirius XM Shares Drop After Q2 Results Spark Sell-the-News Reaction

Sirius XM shares fell sharply in pre-market trading after the company released its second-quarter 2026 operating and financial results. The stock dropped 5.7% to $30.75, reversing part of a year-to-date rally that had driven the price to a 52-week high in the prior session. Analyst price targets below the pre-earnings level and ongoing subscriber l…

Capricor Shares Collapse After Advisory Panel Rejects Deramiocel Efficacy

Capricor Shares Collapse After Advisory Panel Rejects Deramiocel Efficacy

Capricor Therapeutics shares tumbled sharply in pre-market trade after the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that the Phase 3 HOPE-3 trial did not provide substantial evidence that deramiocel is effective for treating cardiomyopathy in Duchenne muscular dystrophy. The advisory panel meeting featured a dispute o…

Check Point Shares Plunge After Q2 Miss and Trimmed Guidance

Check Point Shares Plunge After Q2 Miss and Trimmed Guidance

Check Point Software shares tumbled in pre-market trading after the company reported Q2 2026 results that fell short of Street revenue estimates and included a reduction to full-year revenue guidance. The miss came amid recent analyst downgrades and insider selling, and overshadowed a product announcement for an AI-focused network firewall. The dro…

Cinemark Shares Jump After Quarterly Results Top Estimates

Cinemark Shares Jump After Quarterly Results Top Estimates

Cinemark Holdings reported second-quarter 2026 results that surpassed consensus on both earnings and revenue, driven by a record-setting domestic summer box office. The company posted $1.19 per share in earnings on $1.09 billion of revenue, beating estimates of about $1.02 and $1.03 billion, respectively. The news, coupled with an analyst price-tar…

Buy Meta Now: Let the Ad Engine Fund the AI Transition

Buy Meta Now: Let the Ad Engine Fund the AI Transition

Meta's core advertising business remains the profit engine that can finance aggressive AI and Reality Labs investments. The stock is down from its highs, trading at a reasonable multiple for a cash-generative ad giant with optionality in AI. This trade idea outlines a long-term (180 trading days) buy with clear entry, target, and stop levels while …

Xerox Shares Jump After Q2 Profit Surprise and Outlook Raise

Xerox Shares Jump After Q2 Profit Surprise and Outlook Raise

Xerox shares leapt 22.4% in pre-open trading after the company reported a return to profitability in the second quarter of 2026, posted double-digit year-over-year revenue growth, and raised its fiscal 2026 outlook. The quarter included a $105 million pre-tax benefit tied to IEEPA tariff receivables and showed an adjusted profit versus an adjusted …

Bank of England Divided Over Next Move as Rates Held at 3.75%

Bank of England Divided Over Next Move as Rates Held at 3.75%

The Bank of England's Monetary Policy Committee voted 6-3 to keep Bank Rate at 3.75%, with a majority opting to wait for clearer evidence on energy-driven inflation and second-round effects. Three members advocated an immediate increase to 4% to address upside risks tied to geopolitical tensions and commodity volatility.

Amneal Shares Jump After Broad Q2 Beat and Second Guidance Raise

Amneal Shares Jump After Broad Q2 Beat and Second Guidance Raise

Amneal Pharmaceuticals jumped roughly 10% in pre-market trading after reporting a stronger-than-expected second quarter. The Bridgewater, New Jersey-based company beat revenue and adjusted EPS forecasts, raised its full-year guidance for the second time in 2026, and highlighted a pending biosimilars-related transaction as a strategic growth avenue.…

Bank of England Holds Rates at 3.75% as Split on Further Tightening Widens

Bank of England Holds Rates at 3.75% as Split on Further Tightening Widens

The Bank of England's Monetary Policy Committee voted 6-3 to maintain Bank Rate at 3.75%, with three members preferring a rise to 4% as renewed conflict between the United States and Iran lifted risks to energy markets. Governor Andrew Bailey and the majority of the MPC continued a wait-and-see strategy aimed at preventing inflation from drifting s…